Literature DB >> 26689785

PCSK9 Inhibitors: A Technology Worth Paying For?

William S Weintraub1, Samuel S Gidding2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26689785      PMCID： PMC4816976          DOI： 10.1007/s40273-015-0355-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  13 in total

1.  Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.

Authors:  Brendan M Everett; Robert J Smith; William R Hiatt
Journal:  N Engl J Med       Date:  2015-10-07       Impact factor: 91.245

Review 2.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

Authors:  M C Weinstein; J E Siegel; M R Gold; M S Kamlet; L B Russell
Journal:  JAMA       Date:  1996-10-16       Impact factor: 56.272

3.  Value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association.

Authors:  William S Weintraub; Stephen R Daniels; Lora E Burke; Barry A Franklin; David C Goff; Laura L Hayman; Donald Lloyd-Jones; Dilip K Pandey; Eduardo J Sanchez; Andrea Parsons Schram; Laurie P Whitsel
Journal:  Circulation       Date:  2011-07-25       Impact factor: 29.690

4.  Statin intolerance: reconciling clinical trials and clinical experience.

Authors:  Connie B Newman; Jonathan A Tobert
Journal:  JAMA       Date:  2015-03-10       Impact factor: 56.272

Review 5.  Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.

Authors:  Brian A Ference; Wonsuk Yoo; Issa Alesh; Nitin Mahajan; Karolina K Mirowska; Abhishek Mewada; Joel Kahn; Luis Afonso; Kim Allan Williams; John M Flack
Journal:  J Am Coll Cardiol       Date:  2012-10-17       Impact factor: 24.094

Review 6.  Molecular biology of PCSK9: its role in LDL metabolism.

Authors:  Jay D Horton; Jonathan C Cohen; Helen H Hobbs
Journal:  Trends Biochem Sci       Date:  2007-01-09       Impact factor: 13.807

7.  Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model.

Authors:  M C Weinstein; P G Coxson; L W Williams; T M Pass; W B Stason; L Goldman
Journal:  Am J Public Health       Date:  1987-11       Impact factor: 9.308

8.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

9.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

10.  The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.

Authors:  B Mihaylova; J Emberson; L Blackwell; A Keech; J Simes; E H Barnes; M Voysey; A Gray; R Collins; C Baigent
Journal:  Lancet       Date:  2012-05-17       Impact factor: 79.321
View more
  8 in total

1.  Perspective on Trends in Statin Use.

Authors:  William S Weintraub
Journal:  JAMA Cardiol       Date:  2017-01-01       Impact factor: 14.676

2.  PCSK9 Inhibitors Show Value for Patients and the US Health Care System.

Authors:  Wei-Han Cheng; Étienne Gaudette; Dana P Goldman
Journal:  Value Health       Date:  2017-06-17       Impact factor: 5.725

3.  Effects of Bilberry and Oat intake on lipids, inflammation and exercise capacity after Acute Myocardial Infarction (BIOAMI): study protocol for a randomized, double-blind, placebo-controlled trial.

Authors:  Cecilia Bergh; Rikard Landberg; Kristina Andersson; Lovisa Heyman-Lindén; Ana Rascón; Anders Magnuson; Payam Khalili; Amra Kåregren; Johan Nilsson; Carlo Pirazzi; David Erlinge; Ole Fröbert
Journal:  Trials       Date:  2021-05-10       Impact factor: 2.279

4.  Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center.

Authors:  Parth Shah; Charles J Glueck; Vybhav Jetty; Naila Goldenberg; Matan Rothschild; Rashid Riaz; Gregory Duhon; Ping Wang
Journal:  Lipids Health Dis       Date:  2016-08-18       Impact factor: 3.876

5.  Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study.

Authors:  Parth Shah; Charles J Glueck; Naila Goldenberg; Sarah Min; Chris Mahida; Ilana Schlam; Matan Rothschild; Ali Huda; Ping Wang
Journal:  Lipids Health Dis       Date:  2017-01-23       Impact factor: 3.876

Review 6.  Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost.

Authors:  William S Weintraub; Kelvin H Lee
Journal:  JACC Basic Transl Sci       Date:  2018-03-01

7.  Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.

Authors:  Max Korman; Torbjørn Wisløff
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

Review 8.  PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice.

Authors:  Filipe Ferrari; Ricardo Stein; Marcelo Trotte Motta; Emilio Hideyuki Moriguchi
Journal:  Arq Bras Cardiol       Date:  2019-02-28       Impact factor: 2.000
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.